Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2008.112458v1, 2009; 10.1373/clinchem.2008.112458
This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2008.112458v1
55/3/445    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bidlingmaier, M.
Right arrow Articles by Bergmann, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bidlingmaier, M.
Right arrow Articles by Bergmann, A.

Received on July 2, 2008
Accepted on November 13, 2008

Drug Monitoring and Toxicology

High-Sensitivity Chemiluminescence Immunoassays for Detection of Growth Hormone Doping in Sports

Martin Bidlingmaier 1*, Jennifer Suhr 2, Andrea Ernst 2, Zida Wu 3, Alexandra Keller 4, Christian J. Strasburger 3, Andreas Bergmann 2

1 Medizinische Klinik–Innenstadt, Ludwig-Maximilians-University, Munich, Germany
2 SphingoTec GmbH, Borgsdorf, Germany
3 Division of Clinical Endocrinology, Department of Medicine, Campus Mitte, Charité-Universitätsmedizin, Berlin, Germany
4 Hospital for Children and Adolescents, University of Leipzig, Germany

* To whom correspondence should be addressed. E-mail: martin.bidlingmaier{at}med.uni-muenchen.de.

BACKGROUND: Recombinant human growth hormone (rhGH) is abused in sports, but adequate routine doping tests are lacking. Analysis of serum hGH isoform composition has been shown to be effective in detecting rhGH doping. We developed and validated selective immunoassays for isoform analysis with potential utility for screening and confirmation in doping tests.

METHODS: Monoclonal antibodies with preference for pituitary hGH (phGH) or rhGH were used to establish 2 pairs of sandwich-type chemiluminescence assays with differential recognition of rhGH (recA and recB) and phGH (pitA and pitB). We analyzed specimens from volunteers before and after administration of rhGH and calculated ratios between the respective rec- and pit-assay results.

RESULTS: Functional sensitivities were <0.05 µg/L, with intra- and interassay imprecision ≤8.4% and ≤13.7%, respectively. In 2 independent cohorts of healthy subjects, median rec/pit ratios (range) were 0.84 (0.09–1.32)/0.81 (0.27–1.21) (recA/pitA) and 0.68 (0.08–1.20)/0.80 (0.25–1.36) (recB/pitB), with no sex difference. In 20 recreational athletes, ratios (median SD) increased after a single injection of rhGH, reaching 350% (73%) (recA/pitA) and 400% (93%) (recB/pitB) of baseline ratios. At a moderate dose (0.033 mg/kg), mean recA/pitA and recB/pitB ratios remained significantly increased for 18 h (men) and 26 h (women). After high-dose rhGH (0.083 mg/kg), mean rec/pit ratios remained increased for 32 h (recA/pitA) and 34 h (recB/pitB) in men and were still increased after 36 h in women.

CONCLUSIONS: Using sensitive chemiluminescence assays with preferential recognition of phGH or rhGH, detection of a single injection of rhGH was possible for up to 36 h.




The following articles in journals at HighWire Press have cited this article:


Home page
Clin. Chem.Home page
L. D. Bowers
The International Antidoping System and Why It Works
Clin. Chem., August 1, 2009; 55(8): 1456 - 1461.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
U.-H. Stenman
Detection of Illicit Use of Growth Hormone
Clin. Chem., March 1, 2009; 55(3): 387 - 388.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by the American Association for Clinical Chemistry.